MNTA 2011-2013 News Flow
[Miscellaneous updates.]
Lovenox
• Soon: Preliminary hearing in US District Court on MNTA’s patent-infringement suit against Amphastar and WPI.
• 25-Oct-2011: NVS reports 3Q11 sales of generic Lovenox, which forms the basis for MNTA’s 45% profit share for this period.
• Late Oct/early Nov 2011: MNTA’s 3Q11 CC, where there may be some new color on legal maneuvering with respect to Lovenox.
• 4-Feb-2013 (not a typo): Start of NVS/MNTA’s patent-infringement suit against Teva. (This suit is now much less consequential than MNTA’s suit against Amphastar.)
Copaxone
• Late 2011/early 2012: Court ruling on Copaxone patent trial.
• Timing uncertain: FDA action on Copaxone ANDA.
Other programs
• Timing uncertain: Announcements regarding MNTA’s FoB programs.
• 1Q12: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”